Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 28;10(8):e0135530.
doi: 10.1371/journal.pone.0135530. eCollection 2015.

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients

Hsin-Hung Chen  1 , Ming-Hwarng Horng  2 , Su-Yin Yeh  3 , I-Ching Lin  4 , Chih-Jung Yeh  5 , Chih-Hsin Muo  6 , Fung-Chang Sung  7 , Chia-Hung Kao  8
Affiliations

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients

Hsin-Hung Chen et al. PLoS One. .

Abstract

Objective: Diabetes is a common diseases and a major problem worldwide. Diabetic osteopathy might be elevated in diabetic patients and is usually caused by bone fracture. Several diabetes medications, such as thiazolidinediones (TZDs), could lead to increased risks of fracture.

Methods: We used the nationwide database to identified 32466 patients who had developed type 2 diabetes from 2000 to 2010 as the diabetic cohort and, from that group, we selected 3427 diabetic patients who had developed bone fracture to survey the possible risk factors, includng commonly used diabetes medication.

Results: We found that TZDs might present increased risks for fracture in patients who used it for an extended period (7 to 730 days before the index date), especially in female patients younger than 64 years old, for whom the risk was elevated from a 1.74- to a 2.58-fold odds ratio.

Conclusions: We recommend that clinics follow up with non-osteoporotic female patients younger than 64 years old who are using TZDs, to avoid the associated risks of fracture.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991; 49: 155–60. - PubMed
    1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetesmellitus and risk of fracture. Am J Epidemiol 2007;166:495–505 - PubMed
    1. Cozen L. Does diabetes delay fracturehealing? Clin Orthop Relat Res 1972;82:134–40 - PubMed
    1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–89 - PubMed
    1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443 - PubMed

Publication types